EN DE
STOCK COMPARISON

Regeneron Pharmaceuticals vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Regeneron Pharmaceuticals (REGN) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 8, 2026.

As of Aug 8, 2026, Fair Value Calculator sees Regeneron Pharmaceuticals as the less overvalued of the two: Regeneron Pharmaceuticals trades at $772 versus a fair value of $594 (-23%), while Vertex Pharmaceuticals trades at $484 versus $279 (-42%).
Regeneron Pharmaceuticals
REGN · USD · Health Care
-23%
upside to fair value
overvalued
Price$772
Fair Value$594
Quality72/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-42%
upside to fair value
overvalued
Price$484
Fair Value$279
Quality74/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Regeneron PharmaceuticalsVertex Pharmaceuticals
Valuation
16.2×P/E (TTM)28.8×
4.61×P/S (TTM)10.06×
2.20×P/B6.59×
15.4×EV/EBITDA23.8×
1.15×PEG1.72×
0.5%Dividend yield—
$3.58Dividend per share—
Profitability
30%Net margin36%
21%Operating margin38%
15%Return on equity24%
6%Return on assets12%
Growth
19%Revenue growth (YoY)8%
5.6%Avg. growth/yr (3Y)10.6%
11.0%Avg. growth/yr (5Y)14.2%
Balance & size
0.06×Debt / equity0.03×
$69BMarket cap$123B
healthyGrowth qualityhealthy

Vertex Pharmaceuticals leads: 6 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Regeneron Pharmaceuticalsof which business quality 72 · market factors 68 Vertex Pharmaceuticalsof which business quality 77 · market factors 60
ProfitabilityMargins and returns on capital today
60
72
Quality GrowthAre margins and returns improving?
45
65
CashflowEarnings quality: real cash, not paper profit
80
79
Fin. StrengthBalance sheet, leverage, solvency risk
84
92
InvestmentDisciplined investing over empire-building
54
58
Low VolatilityCalm price path (market factor)
79
77
MomentumPrice trend over the last 3–12 months (market factor)
53
52
52W MomentumDistance to the 52-week high (market factor)
80
55
Net IssuanceBuybacks instead of dilution
99
82

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Regeneron Pharmaceuticals

DCF Models$1,093
Earnings-Based$1,116
Dividend Discount$63.24
Multiples$584
Asset-Based$203
Growth DCF$946
Economic Profit$371
Growth Earnings$1,399

13 of 26 models see the stock below the current price.

Vertex Pharmaceuticals

DCF Models$429
Earnings-Based$516
Dividend Discount$7.07
Multiples$246
Asset-Based$49.27
Growth DCF$333
Economic Profit$254
Growth Earnings$672

19 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Regeneron Pharmaceuticals
Bear $447Fair Value $594Bull $1,731
$772 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$484 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Regeneron Pharmaceuticals · Health Care

Quality score72 · Top 25%
Fair value upside-23% · above median

Vertex Pharmaceuticals · Health Care

Quality score74 · Top 25%
Fair value upside-42% · below median

Bottom line

As of Aug 8, 2026, Fair Value Calculator sees Regeneron Pharmaceuticals as the less overvalued of the two: Regeneron Pharmaceuticals trades at $772 versus a fair value of $594 (-23%), while Vertex Pharmaceuticals trades at $484 versus $279 (-42%).

Vertex Pharmaceuticals has the higher quality score (74/100).

See the full analysis →
Regeneron Pharmaceuticals · Vertex Pharmaceuticals

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Regeneron Pharmaceuticals

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to Vertex Pharmaceuticals

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.